On Monday’s most recent check, cbdMD Inc. (NYSE: YCBD) rose 11.43% to $0.25 after the CBD company finished its human clinical trial.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
How successful was YCBD during the trial?
The initial findings from the recently finished human clinical study that cbdMD (YCBD) conducted at the University of South Carolina were just released. The first results from these trials, which started in the autumn of 2020, indicate that cbdMD’s exclusive broad-spectrum hemp extract lessens pain in healthy individuals. The innovative randomized, double-blind, placebo-controlled study was created to examine the effects of YCBD’s unique broad-spectrum cannabinoid blend on pain, inflammation, mood, sleep, and immunity in healthy adult subjects in order to further demonstrate the effectiveness of the company’s products.
For three months, study participants took cbdMD’s specialized broad-spectrum hemp extract blend, which contains 100 mg of CBD and additional trace amounts of cannabinoids. The study’s preliminary findings indicate that daily use of the company’s premier broad spectrum mix considerably reduces both the perception and severity of pain in healthy persons. In anticipation of these findings, the company just introduced a new flagship product in the form of a tincture, gummy, and softgel that contains a clinically-researched mix of 100 mg of CBD per serving from a broad-spectrum hemp extract.
All of the company’s broad spectrum goods, including its first-ever NSF for Sport products, feature the flagship mix. The Company has relaunched itself as the CBD brand of choice by offering the greatest potency goods at the best value in the market in order to make these effective products accessible to more people in need.
YCBD intends to submit the study’s data to the Food and Drug Administration (FDA) for Structure Function Claim Notifications (SFCNs), which is the procedure by which producers notify the FDA of their intention to make claims about the advantages of their products on the structure or function of the human body. The findings of this study will help YCBD define its product development roadmap and guarantee that it offers clients goods that are designed to have a significant influence on their everyday lives.
How will YCBD move forward?
As further findings from the human trial are completed over the coming weeks, YCBD and its subsidiary cbdMD Therapeutics, LLC will make them public. Ultimately, the findings will be published in a peer-reviewed publication. These promising results, according to cbdMD (YCBD), will likely serve as the foundation for several new cbdMD product formulations. The findings of the trial will also be used as initial information for subsequent investigative studies carried out in the future by the Therapeutics Division of cbdMD.
